[1] D A COX. Selectivity of inhibition of Na(+)-Ca2+ exchange of heart mitochondria by benzothiazepine CGP-37157.[J]. Journal of Cardiovascular Pharmacology, 1993, 21 4: 595-599. DOI:
10.1097/00005344-199304000-00013[2] IYUKI NAMEKATA Hikaru T Shogo Hamaguchi. Pharmacological discrimination of plasmalemmal and mitochondrial sodium-calcium exchanger in cardiomyocyte-derived H9c2 cells.[J]. Biological & pharmaceutical bulletin, 2015, 38 1: 147-150. DOI:
10.1248/bpb.b14-00525[3] KYLE T BARON Stanley A T. CGP37157 modulates mitochondrial Ca2+ homeostasis in cultured rat dorsal root ganglion neurons[J]. European journal of pharmacology, 1997, 340 2: Pages 295-300. DOI:
10.1016/s0014-2999(97)01433-7[4] TING LIU. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure.[J]. Circulation research, 2014, 115 1: 44-54. DOI:
10.1161/circresaha.115.303062[5] SANTOS M NICOLAU. Mitochondrial Na+/Ca2+-exchanger blocker CGP37157 protects against chromaffin cell death elicited by veratridine.[J]. Journal of Pharmacology and Experimental Therapeutics, 2009, 330 3: 844-854. DOI:
10.1124/jpet.109.154765[6] A RUIZ C M E Alberdi. CGP37157, an inhibitor of the mitochondrial Na+/Ca2+ exchanger, protects neurons from excitotoxicity by blocking voltage-gated Ca2+ channels[J]. Cell Death & Disease, 2014, 5 4: e1156-e1156. DOI:
10.1038/cddis.2014.134